WeConnectPatients.com · Blood & Cancer Care

Multiple myeloma is a fight you didn’t choose. But you have more options than you think.

It’s a blood cancer that starts in your bone marrow. It’s serious. But treatment has changed dramatically — and the future is changing faster.

New Cases/Year

Diagnosed in the United States annually

Higher in Black Americans

Significant racial disparity in who gets it

5-Year Relative Survival

Based on recent U.S. data; outcomes vary by stage, age, and treatment approach

Median Age

At diagnosis — but it can happen younger

Your bone marrow is making the wrong cells. That’s what’s happening.

Multiple myeloma isn’t the kind of cancer most people have heard of. It starts quietly, in the place where your blood is made. Abnormal plasma cells — a type of white blood cell — start multiplying out of control. And they crowd out the healthy cells your body actually needs.

Those misfiring plasma cells produce an abnormal protein — called a monoclonal protein or M-protein — that builds up in your blood and urine without doing anything useful. Meanwhile, the damage spreads: weakened bones, kidney trouble, a suppressed immune system that makes you vulnerable to infections you’d normally fight off easily.

About 35,000 people are diagnosed with myeloma each year in the U.S. The median age at diagnosis is 69, but roughly 10–15% of patients are under 50. Black Americans face 2–3 times the risk of developing it — a disparity that persists regardless of access to care and demands attention.

Here’s what has changed: this used to be a disease measured in months. Now many people live 10 years or more. New drug classes, better combinations, and advances like CAR-T cell therapy are rewriting what’s possible. But the treatment path is long, and it matters who’s guiding you through it.

There’s something called MGUS — a precursor condition that affects 3–4% of adults over 70. Most people with MGUS never develop myeloma. But knowing about it means knowing what to watch for.

What drives multiple myeloma

Nobody fully understands what causes myeloma. But several things are known to increase risk.

Abnormal plasma cells

Your bone marrow starts producing malignant plasma cells that crowd out normal blood production. These abnormal cells make a protein called an M-protein (or monoclonal protein) that serves no useful purpose and can build up to damage your kidneys, bones, and immune system.

Age

Most people are diagnosed after 65. The risk increases with every decade. But younger patients exist too — roughly 10–15% are under 50.

Race and ethnicity

Black Americans develop multiple myeloma at 2–3 times the rate of white Americans, often at younger ages, and frequently with more aggressive disease. This isn’t explained by lifestyle — it reflects biological and systemic factors.

Family history

Having a first-degree relative with myeloma roughly doubles your risk. Genetic predisposition matters, even though most cases are not inherited.

MGUS: the precursor

Monoclonal gammopathy of undetermined significance is a condition where abnormal proteins show up in blood work but haven’t caused damage yet. About 1% of MGUS cases progress to myeloma each year.

Obesity and environmental exposures

Higher body weight and certain chemical exposures (pesticides, herbicides, petroleum products) have been linked to increased risk, though the mechanisms aren’t fully understood.

How myeloma is diagnosed

Myeloma is often caught because something else seemed off first — back pain, fatigue, or unusual blood work.

Blood and urine tests

Your doctor looks for abnormal proteins (M-protein), checks kidney function, and measures blood cell counts. A protein called beta-2 microglobulin helps indicate how advanced things are.

Bone marrow biopsy

A small sample of marrow is taken, usually from your hip bone. This confirms whether abnormal plasma cells are present and how many there are. It’s the definitive test.

Imaging

X-rays, CT scans, PET scans, or MRI look for bone damage. Myeloma can cause lytic lesions — holes in your bones — that increase fracture risk. About 50–80% of patients have bone involvement at diagnosis.

Genetic testing

A test called cytogenetic analysis examines the genetic material inside your myeloma cells. It identifies specific changes that determine whether your disease is standard-risk or high-risk — and that helps guide how aggressively it needs to be treated.

Staging

A staging system called the Revised International Staging System (R-ISS) combines specific blood test results — including beta-2 microglobulin, albumin, and LDH — with the genetic features of your myeloma cells to estimate prognosis and guide treatment intensity. This guides treatment decisions — not your age alone.

Treatment has advanced significantly

Today’s approach uses combinations of targeted drug classes — not traditional chemo — tailored to your age, fitness, and genetic risk.

First Line

Foundation Therapy

Modern frontline treatment typically combines two types of targeted drugs — a proteasome inhibitor and an immunomodulatory drug (which helps the immune system recognize and attack myeloma cells) — plus a steroid. For many patients, a targeted antibody is added to this combination. These multi-drug regimens work without traditional chemotherapy and achieve deep responses in most patients.

Consolidation

Stem Cell Transplant

For patients who are fit enough (generally under 70 without major health issues), an autologous stem cell transplant — in which your own stem cells are collected, then used to help your body recover after high-dose treatment — can deepen the initial response and extend remission. It’s intense but remains a cornerstone of treatment. Access to transplant varies by location and healthcare center — if you are a transplant candidate, ask your care team about referral options.

All Stages

Targeted Antibodies

Anti-CD38 antibodies have become an important part of treatment across every stage of multiple myeloma. They’re now used alongside standard drug combinations in newly diagnosed patients and remain effective in later lines of treatment.

Advanced Therapy

CAR-T & Bispecifics

For patients whose disease returns after multiple treatments, CAR-T cell therapy and bispecific antibodies have shown high response rates in clinical trials — results that represent a meaningful advance over what was achievable with earlier approaches. Individual outcomes depend on prior treatment history, disease biology, and other factors.

All treatments carry potential side effects. Talk to your provider about which risks and benefits apply to you.

“The hardest part wasn’t the diagnosis. It was learning to live with a disease that doesn’t have a finish line — and finding the treatments that let me keep going.”

Reflects common patient experiences

Multiple myeloma treatment is typically ongoing. Many patients remain on maintenance therapy for years. If cost or access is a barrier, ask about patient assistance programs and clinical trial options.

Answers to common questions

Living with myeloma raises real, practical questions. Here are honest answers to some of the most common ones.

Is myeloma curable?

Not yet. But “not curable” is different from “not treatable.” Many people live a decade or more with modern therapy. The goal is deep, lasting remission — and for some patients, the disease stays quiet for years.

What does maintenance therapy actually mean?

It means treatment doesn’t stop after the initial phase. Most patients take an oral medication indefinitely to keep the disease in check. It works — but it also means living with side effects, appointments, and the reality that treatment is part of your life now.

Will my bones be okay?

Multiple myeloma weakens bones. About 50–80% of patients have bone damage at diagnosis. Bone-strengthening medications help prevent fractures, but many patients also experience pain, limited mobility, or changes to what they can do physically. These impacts are real and deserve attention — talk to your care team about pain management, physical therapy, and what kinds of activity are safe for your situation. Staying on top of calcium and vitamin D also supports bone health.

How does myeloma affect my immune system?

Significantly. The disease itself suppresses normal antibody production, and treatments can further weaken immunity. Infections are a leading cause of complications. Vaccinations, preventive antibiotics, and sometimes immunoglobulin replacement are part of staying safe.

Does myeloma affect mental health?

Yes, it can. A cancer diagnosis that requires indefinite treatment carries real psychological weight. Depression affects 20–30% of myeloma patients. This isn’t weakness — it’s a predictable response to a hard situation. Ask for mental health support early.

Why does myeloma disproportionately affect Black Americans?

Black Americans develop multiple myeloma 2–3 times more often than white Americans, often at younger ages. The reasons include both biological differences in immune response and systemic healthcare inequities. If you’re Black and diagnosed with myeloma, you deserve a care team that acknowledges this disparity — and a specialist who treats it aggressively.

What questions should I ask about clinical trials?

Start with: “Am I eligible for any trials right now?” Then: “Would a trial give me access to newer treatments?” Clinical trials aren’t a last resort — they’re often how people access the best available therapy. Your care team should bring this up. If they don’t, you should.

How do I manage the emotional toll of long-term treatment?

Acknowledge it. Treatment fatigue is real. The cycle of appointments, lab work, side effects, and uncertainty wears people down — and the people close to them too. Support groups, counseling, and honest conversations with your care team help. You don’t have to carry this alone.

Research & Progress

The science has never moved this fast

Myeloma research has never been this active. The last two decades brought proteasome inhibitors, immunomodulatory drugs, and anti-CD38 antibodies — each one extending survival significantly. Now CAR-T cell therapy and bispecific antibodies are delivering strong results in clinical trials, even in patients who’ve been through multiple prior treatments.

Researchers are pushing further: MRD-guided treatment strategies (using sensitive tests to measure minimal residual disease) that could let some patients safely reduce therapy. New drug combinations entering earlier lines of treatment. Better understanding of why high-risk genetic subtypes behave differently — and how to target them. The pipeline is deep and the pace is accelerating.

Clinical trials are the engine behind every one of these advances. Participating in a trial means working with specialized care teams, accessing therapies before they’re widely available, and contributing to knowledge that helps everyone with myeloma. It’s a choice — never an obligation — and your standard care continues regardless.

You deserve a treatment plan that fights as hard as you do. Not one that just buys time.

Clinical research for myeloma is advancing rapidly. New therapies, new combinations, new approaches — and you may be able to access them now.

Not sure where to start?

Walking into a hematology appointment with the right questions changes everything. We put together a quick guide.

This content is for educational purposes only and isn’t a substitute for medical advice. Talk to your healthcare provider before making decisions about your care. Information about clinical trials is for general awareness, not an endorsement of any specific study.

Sources: American Cancer Society, NCI, International Myeloma Foundation, MMRF, LLS, Mayo Clinic, NEJM, Blood, Cancer, peer-reviewed literature (2006–2025), ClinicalTrials.gov.

WeConnect is a Takeda initiative connecting people to clinical trial opportunities. Visit WeConnectPatients.com.